Boris Itkin1, Lucía Kaminszczik1*, María Belén Centurión2 and Sebastián Lescano3
1Department of Clinical Oncology, Juan A Fernández Hospital, Buenos Aires, Argentina
2Department of Pathology, Juan A Fernández Hospital, Buenos Aires, Argentina
3Department of Medical Imaging, Juan A Fernández Hospital, Buenos Aires, Argentina
*Corresponding Author: Lucía Kaminszczik, Department of Clinical Oncology, Juan A Fernandez Hospital, Buenos Aires, Argentina.
Received: July 13, 2020; Published: August 19, 2020
Disseminated bone marrow carcinomatosis (DBMC) is an infrequent manifestation of advanced breast cancer which can be accompanied by life-threatening clinical complications. The optimal management of the condition is unknown due to the paucity of published studies. We report a case of young female patient with DBMC as a part of the systemic relapse of hormone receptor positive, HER2 negative breast cancer. At the onset of DBMC, due to severe thrombocytopenia (18,000/mm3) and clinical deterioration, she required hospitalization and platelets transfusions. Her Eastern Cooperative Oncology Group Performance Status was 3. After doxorubicin failure, considering her familial history of multiple relatives with breast cancer, single-agent weekly carboplatin has been started at the dose AUC 2 with gradual normalization of the marrow function, important clinical amelioration and without significant toxicity. The survival time from DBMC diagnosis was 11 months. BRCA testing was not performed. In some very carefully selected patients with DBMC, single-agent weekly carboplatin may be considered as a treatment option.
Keywords: Bone Marrow Carcinomatosis; Disseminated Carcinomatosis of Bone Marrow; Breast Cancer; Carboplatin; Thrombocytopenia
Citation: Lucía Kaminszczik., et al. “Single-Agent Weekly Carboplatin for Disseminated Carcinomatosis of Bone Marrow Arising from Breast Cancer. A Case-Report”. Acta Scientific Clinical Case Reports 1.9 (2020): 08-12.
Copyright: © 2020 Lucía Kaminszczik., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.